Literature DB >> 11012566

Tall stature in familial glucocorticoid deficiency.

L L Elias1, A Huebner, L A Metherell, A Canas, G L Warne, M L Bitti, S Cianfarani, P E Clayton, M O Savage, A J Clark.   

Abstract

OBJECTIVE: Familial glucocorticoid deficiency (FGD) has frequently been associated with tall stature in affected individuals. The clinical, biochemical and genetic features of five such patients were studied with the aim of clarifying the underlying mechanisms of excessive growth in these patients. PATIENTS AND METHODS: Five patients with a clinical diagnosis of FGD are described in whom the disorder resulted from a variety of novel or previously described missense or nonsense mutations of the ACTH receptor (MC2-R). All patients demonstrated excessive linear growth over that predicted from parental indices and increased head circumference.
RESULTS: Growth hormone and IGF-I-values were normal. Growth charts suggest that the excessive growth is reduced to normal following the introduction of glucocorticoid replacement. A characteristic facial appearance including hypertelorism, marked epicanthic folds and prominent frontal bossing was noted.
CONCLUSIONS: These findings indicate that ACTH resistance resulting from a defective ACTH receptor may be associated with abnormalities of cartilage and/or bone growth independently of the GH-IGF-I axis, but probably dependent on ACTH actions through other melanocortin receptors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11012566     DOI: 10.1046/j.1365-2265.2000.01122.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  14 in total

1.  A large-scale genome-wide linkage analysis to map loci linked to stature in Chinese population.

Authors:  Xiumei Hong; Hui-Ju Tsai; Xin Liu; Zhiping Li; Xue Liu; Genfu Tang; Houxun Xing; Jianhua Yang; Binyan Wang; Yan Feng; Xin Xu; Xiping Xu; Xiaobin Wang
Journal:  J Clin Endocrinol Metab       Date:  2008-08-26       Impact factor: 5.958

Review 2.  Role of proopiomelanocortin-derived peptides and their receptors in the osteoarticular system: from basic to translational research.

Authors:  Markus Böhm; Susanne Grässel
Journal:  Endocr Rev       Date:  2012-06-26       Impact factor: 19.871

Review 3.  The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders.

Authors:  Walter L Miller; Richard J Auchus
Journal:  Endocr Rev       Date:  2010-11-04       Impact factor: 19.871

4.  Familial Glucocorticoid Deficiency.

Authors:  R K Gupta; S Khera; Madhuri Kanitkar
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 5.  Leveraging melanocortin pathways to treat glomerular diseases.

Authors:  Rujun Gong
Journal:  Adv Chronic Kidney Dis       Date:  2014-03       Impact factor: 3.620

6.  ACTH protects against glucocorticoid-induced osteonecrosis of bone.

Authors:  Mone Zaidi; Li Sun; Lisa J Robinson; Irina L Tourkova; Li Liu; Yujuan Wang; Ling-Ling Zhu; Xuan Liu; Jianhua Li; Yuanzhen Peng; Guozhe Yang; Xingming Shi; Alice Levine; Jameel Iqbal; Beatrice B Yaroslavskiy; Carlos Isales; Harry C Blair
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-26       Impact factor: 11.205

7.  Familial glucocorticoid deficiency type 2: a case report.

Authors:  Leyla Akın; Selim Kurtoğlu; Mustafa Kendirici; Mustafa Ali Akın
Journal:  J Clin Res Pediatr Endocrinol       Date:  2010-08-06

8.  Genetic regulation of the growth plate.

Authors:  Elham Karimian; Andrei S Chagin; Lars Sävendahl
Journal:  Front Endocrinol (Lausanne)       Date:  2012-01-09       Impact factor: 5.555

9.  Severe loss-of-function mutations in the adrenocorticotropin receptor (ACTHR, MC2R) can be found in patients diagnosed with salt-losing adrenal hypoplasia.

Authors:  Lin Lin; Peter C Hindmarsh; Louise A Metherell; Mahmoud Alzyoud; Maryam Al-Ali; Caroline E Brain; Adrian J L Clark; Mehul T Dattani; John C Achermann
Journal:  Clin Endocrinol (Oxf)       Date:  2007-02       Impact factor: 3.478

10.  Phenotypic characteristics of familial glucocorticoid deficiency (FGD) type 1 and 2.

Authors:  Teng-Teng L L Chung; Li F Chan; Louise A Metherell; Adrian J L Clark
Journal:  Clin Endocrinol (Oxf)       Date:  2009-06-24       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.